drugset / Trial / NCT00432016

Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV

NCT00432016

Phase 1/2 Completed 24 enrolled RFS Pharma, LLC
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the short term safety, tolerance, and antiviral effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the dosage for AZT can be reduced, potentially decreasing side effects, while maintaining antiviral effects. Study hypothesis: DADP in combination with AZT is safe and effective, and AZT dosing may be reduced, resulting in lower levels of AZT-monophosphate associated with toxicity and maintaining levels of AZT-triphosphate associated with efficacy.

Timeline

Start
2007-02
Primary completion
Completion
2007-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Zidovudine Small molecule 200 mg
Subject Zidovudine Small molecule 300 mg
Subject amdoxovir Small molecule 500 mg